Year-end Sale % OFF 
Abstract
Key points Left ventricular systolic dysfunction has traditionally been used as a risk factor favoring coronary artery bypass surgery over percutaneous coronary intervention (PCI), but recent data have challenged this. Retrospective data from the BIOFLOW trials show no difference between normal and moderately abnormal LVEF (30%–50%) in acute complications or target vessel failure. Abnormal LVEF may be a marker for comorbidities but no longer a relative contraindication to PCI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
